CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $) In Millions, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 1,355	$ 1,656
Marketable securities	1,178	1,173
Receivables	3,308	3,083
Inventories	1,791	1,657
Deferred income taxes	1,828	1,597
Prepaid expenses and other	616	355
Total Current Assets	10,076	9,521
Property, plant and equipment	5,259	5,333
Goodwill	7,646	7,635
Other intangible assets	8,570	8,778
Deferred income taxes	190	203
Marketable securities	3,242	3,523
Other assets	975	904
Total Assets	35,958	35,897
Current Liabilities:
Short-term borrowings and current portion of long-term debt	1,372	826
Accounts payable	2,079	2,202
Accrued expenses	2,376	2,573
Deferred income	772	825
Accrued rebates and returns	938	1,054
U.S. and foreign income taxes payable	276	193
Dividends payable	601	606
Total Current Liabilities	8,414	8,279
Pension, postretirement, and postemployment liabilities	1,638	1,882
Deferred income	4,101	4,024
U.S. and foreign income taxes payable	652	648
Deferred income taxes	473	383
Other liabilities	459	475
Long-term debt	6,522	6,568
Total Liabilities	22,259	22,259
Commitments and contingencies (Note 17)
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,085 in 2013 and 5,117 in 2012, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2013 and 2012	221	221
Capital in excess of par value of stock	2,126	2,694
Accumulated other comprehensive loss	(3,131)	(3,202)
Retained earnings	32,761	32,733
Less cost of treasury stock - 565 million common shares in 2013 and 570 million in 2012	(18,318)	(18,823)
Total Bristol-Myers Squibb Company Shareholders' Equity	13,659	13,623
Noncontrolling interest	40	15
Total Equity	13,699	13,638
Total Liabilities and Equity	$ 35,958	$ 35,897